Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.18
OTCPK:MRNA's Cash-to-Debt is ranked lower than
94% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. OTCPK:MRNA: 0.18 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:MRNA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 10.13 Max: No Debt
Current: 0.18
Debt-to-Equity 0.60
OTCPK:MRNA's Debt-to-Equity is ranked lower than
71% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. OTCPK:MRNA: 0.60 )
Ranked among companies with meaningful Debt-to-Equity only.
OTCPK:MRNA' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.57  Med: 0.1 Max: 1.24
Current: 0.6
-1.57
1.24
Debt-to-EBITDA -0.45
OTCPK:MRNA's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. OTCPK:MRNA: -0.45 )
Ranked among companies with meaningful Debt-to-EBITDA only.
OTCPK:MRNA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.19  Med: -0.21 Max: -0.04
Current: -0.45
-1.19
-0.04
Piotroski F-Score: 3
Altman Z-Score: -0.14
Beneish M-Score: -3.64
WACC vs ROIC
15.02%
-45.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % 524.80
OTCPK:MRNA's Operating Margin % is ranked higher than
100% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. OTCPK:MRNA: 524.80 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:MRNA' s Operating Margin % Range Over the Past 10 Years
Min: -2259.18  Med: -502.33 Max: 524.8
Current: 524.8
-2259.18
524.8
Net Margin % 1406.00
OTCPK:MRNA's Net Margin % is ranked higher than
99% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. OTCPK:MRNA: 1406.00 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:MRNA' s Net Margin % Range Over the Past 10 Years
Min: -2269.84  Med: -708.47 Max: 1406
Current: 1406
-2269.84
1406
ROE % -151.64
OTCPK:MRNA's ROE % is ranked lower than
86% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. OTCPK:MRNA: -151.64 )
Ranked among companies with meaningful ROE % only.
OTCPK:MRNA' s ROE % Range Over the Past 10 Years
Min: -539.78  Med: -329.36 Max: -50.59
Current: -151.64
-539.78
-50.59
ROA % -53.32
OTCPK:MRNA's ROA % is ranked lower than
65% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. OTCPK:MRNA: -53.32 )
Ranked among companies with meaningful ROA % only.
OTCPK:MRNA' s ROA % Range Over the Past 10 Years
Min: -158.44  Med: -78.17 Max: -20.68
Current: -53.32
-158.44
-20.68
3-Year Revenue Growth Rate -100.00
OTCPK:MRNA's 3-Year Revenue Growth Rate is ranked lower than
91% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. OTCPK:MRNA: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:MRNA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -100  Med: -28.25 Max: 71.8
Current: -100
-100
71.8
3-Year EBITDA Growth Rate -41.00
OTCPK:MRNA's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. OTCPK:MRNA: -41.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:MRNA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -11.1 Max: 105.2
Current: -41
0
105.2
3-Year EPS without NRI Growth Rate -39.40
OTCPK:MRNA's 3-Year EPS without NRI Growth Rate is ranked lower than
86% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. OTCPK:MRNA: -39.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:MRNA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -82.1  Med: -10.25 Max: 102.4
Current: -39.4
-82.1
102.4
GuruFocus has detected 2 Warning Signs with Marina Biotech Inc $OTCPK:MRNA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:MRNA's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MRNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:ASX:RGS, NAS:AVIR, NAS:ACHV, XCNQ:ATT, ROCO:4195, XKRX:228180, ASX:OCC, XKRX:066830, XSAT:EUCI, TSX:MBX, XPAR:ALPAT, XPAR:ALHYG, NAS:CLRB, NZSE:BLT, NAS:HTBX, NAS:DFFN, OSTO:LIDDS, ASX:NOX, XKRX:127120, AMEX:BPMX » details
Headquarter Location:USA
Marina Biotech Inc is a biopharmaceutical company. It discovers, acquires, develops and commercializes proprietary drug therapeutics for unmet medical needs in the USA, Europe, and international markets.

Marina Biotech Inc is a biopharmaceutical company. It discovers, acquires, develops and commercializes proprietary drug therapeutics for unmet medical needs in the USA, Europe, and international markets. Its therapeutic focus is the disease intersection of hypertension, arthritis, pain, and oncology. The company's preclinical pipeline includes oligo therapeutics for bladder cancer, Inflammatory Bowel Disease, and Duchenne muscular dystrophy. It generates revenue from license fees, milestone-related development fees, and royalties by licensing rights to its product candidates.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 0.79
MRNA's Price-to-Owner-Earnings is ranked higher than
97% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. MRNA: 0.79 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MRNA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.31  Med: 0.83 Max: 9.73
Current: 0.79
0.31
9.73
PB Ratio 9.04
MRNA's PB Ratio is ranked lower than
82% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. MRNA: 9.04 )
Ranked among companies with meaningful PB Ratio only.
MRNA' s PB Ratio Range Over the Past 10 Years
Min: 0.44  Med: 2.46 Max: 418.92
Current: 9.04
0.44
418.92
EV-to-EBIT -6.76
MRNA's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. MRNA: -6.76 )
Ranked among companies with meaningful EV-to-EBIT only.
MRNA' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.9  Med: -0.8 Max: 15.3
Current: -6.76
-13.9
15.3
EV-to-EBITDA -7.18
MRNA's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. MRNA: -7.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRNA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.9  Med: -0.85 Max: 15.3
Current: -7.18
-13.9
15.3
EV-to-Revenue -94.19
MRNA's EV-to-Revenue is ranked lower than
99.99% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. MRNA: -94.19 )
Ranked among companies with meaningful EV-to-Revenue only.
MRNA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 4.75 Max: 80.4
Current: -94.19
0.2
80.4
Current Ratio 0.10
MRNA's Current Ratio is ranked lower than
98% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. MRNA: 0.10 )
Ranked among companies with meaningful Current Ratio only.
MRNA' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 3.06 Max: 21.21
Current: 0.1
0.03
21.21
Quick Ratio 0.10
MRNA's Quick Ratio is ranked lower than
98% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. MRNA: 0.10 )
Ranked among companies with meaningful Quick Ratio only.
MRNA' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 3.02 Max: 21.07
Current: 0.1
0.03
21.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -74.50
MRNA's 3-Year Average Share Buyback Ratio is ranked lower than
89% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. MRNA: -74.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRNA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -156.6  Med: -20.95 Max: -1.7
Current: -74.5
-156.6
-1.7

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -14.80
MRNA's Earnings Yield (Greenblatt) % is ranked lower than
60% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. MRNA: -14.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MRNA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1884.9  Med: -48.45 Max: 165.3
Current: -14.8
-1884.9
165.3

More Statistics

EPS (TTM) $ -1.02
Beta2.15
Short Percentage of Float7.21%
52-Week Range $0.76 - 5.00
Shares Outstanding (Mil)9.84

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}